Quest Diagnostics, Inc. DGX

NYS: DGX | ISIN: US74834L1008   26/04/2024
134,26 USD (-0,86%)
(-0,86%)   26/04/2024
Bedrijfsnieuws uit Amerika

Bedrijfsnieuws uit Amerika · Bolero.be

Pepsico boekte 1% hogere omzet bij lagere volumes Het drankenbedrijf boekte een omzetgroei van 1% bij een daling van de volumes. Pepsico verdiende 1,61 dollar per aandeel , hoger dan de gemiddelde analistenverwachtingen...

23 april 2024 · Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 · Persbericht

22 april 2024 · Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease · Persbericht

2 april 2024 · Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay · Persbericht

26 maart 2024 · Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease · Persbericht

19 maart 2024 · Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024 · Persbericht

23 februari 2024 · Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference · Persbericht

21 februari 2024 · Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery · Persbericht

15 februari 2024 · Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection · Persbericht

13 februari 2024 · Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery · Persbericht

12 februari 2024 · First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com · Persbericht

1 februari 2024 · Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share · Persbericht

31 januari 2024 · Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies" · Persbericht

22 januari 2024 · Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma · Persbericht

17 januari 2024 · Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 · Persbericht

17 januari 2024 · Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health · Persbericht

8 januari 2024 · Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System · Persbericht

8 januari 2024 · Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC · Persbericht

21 december 2023 · Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

20 december 2023 · Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer · Persbericht

Mijn selecties